TherOx aims for $100m Nasdaq listing
This article was originally published in Clinica
Oxygen therapy specialist TherOx is looking to raise around $100m by floating its shares on the Nasdaq Stock Exchange. The Irvine, California-based company is planning the IPO to fund the development of its TherOx SuperSaturated oxygen therapy system, which is designed to reduce the amount of dead heart muscle that can occur in heart attack patients. According to TherOx, it is “the first company to demonstrate a statistically and clinically significant therapy for reduction in infarct size since the introduction of stents approximately ten years ago”. The company claims the market for heart attack treatment is valued at around $350m. TherOx will list under the symbol “THER”.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals